https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 How can hospitals change practice to better implement smoking cessation interventions? A systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48549 Wed 22 Mar 2023 08:55:13 AEDT ]]> Acceptability and appropriateness of a clinical pathway for managing anxiety and depression in cancer patients: a mixed methods study of staff perspectives https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40280 Wed 13 Mar 2024 08:58:30 AEDT ]]> Lung cancer treatment patterns and factors relating to systemic therapy use in Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46698 Wed 13 Mar 2024 08:07:19 AEDT ]]> Everybody wants it done but nobody wants to do it: an exploration of the barrier and enablers of critical components towards creating a clinical pathway for anxiety and depression in cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24041 Wed 11 Apr 2018 15:24:14 AEST ]]> Implementation of lung cancer multidisciplinary teams: a review of evidence-practice gaps https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39934 Thu 14 Jul 2022 14:21:17 AEST ]]> The elusive search for success: defining and measuring implementation outcomes in a real-world hospital trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38006 Fri 23 Jul 2021 15:05:40 AEST ]]> Facilitating High Quality Cancer Care: A Qualitative Study of Australian Chairpersons' Perspectives on Multidisciplinary Team Meetings https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39680 Fri 17 Jun 2022 15:39:05 AEST ]]> Health services costs for lung cancer care in Australia: estimates from the 45 and up study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]>